302 completed, 50 unknown, 25 terminated, 15 recruiting. 122 Phase 4, 107 Phase 3, 100 Phase 2, 44 Not applicable, 39 Phase 1.
Follow Lamivudine: new trials by email Literature Review of Lamivudine trials Research Report on Lamivudine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection | Phase 3 | Not yet recruiting | University College, London | 800 | 2026-11-01 | 2026-08-28 |
| Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg, Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Dolutegravir 50mg - HIV (Human Immunodeficiency Virus), Sleep | Phase 4 | Not yet recruiting | University of Witwatersrand, South Africa | 40 | 2026-10-05 | 2026-10-06 |
| Efficacy and Safety of Doravirine in the Rapid Initiation Doravirine / lamivudine/ Tenofovir Disoproxil Oral Tablet - HIV-1-infection | Phase 4 | Recruiting | Fundación Huésped | 100 | 2026-09-16 | 2026-09-23 |
| Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine) - HIV-1-infection | Phase 4 | Recruiting | Fundación Huésped | 210 | 2026-09-10 | 2026-09-18 |
| A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC) - HIV Infections | Phase 3 | Recruiting | ViiV Healthcare | 181 | 2026-07-21 | 2026-08-14 |
| Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets - HIV, Art Therapy | Phase 4 | Not yet recruiting | Shanghai Public Health Clinical Center | 60 | 2026-06-01 | 2026-06-08 |
| A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC) - HIV Infections | Phase 2 | Recruiting | ViiV Healthcare | 186 | 2026-02-11 | 2026-07-23 |
| Lamivudine as a Novel Clinical Effort for Rett Syndrome Lamivudine - Rett Syndrome | Phase 2 | Enrolling by invitation | Maria Denise Fernandes Carvalho de Andrade | 10 | 2025-11-05 | 2026-06-10 |
| Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment Dolutegravir 50mg Tab, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC) - Tuberculosis, HIV | Phase 3 | Recruiting | Johns Hopkins University | 150 | 2025-09-18 | 2026-09-11 |
| A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation lamivudine, rapamycin, Exercise Regimen - Smokers, Former Smokers | Phase 1 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 20 | 2025-08-12 | 2026-08-27 |
| Research on the Psychological Status of Patients With HIV-1 Infection All kinds of INSTI medications, All kinds of conventional medications - HIV-1-infection, Anxiety Depression | Not yet recruiting | Shanxi Bethune Hospital | 500 | 2025-08-01 | 2025-07-23 | |
| Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH) Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG) - HIV, HIV-1 | Phase 4 | Recruiting | UBATEC | 50 | 2025-07-31 | 2025-09-12 |
| Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up Dual therapy: darunavir/cobicistat + lamivudine, Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine - HIV Infection, Antiretroviral Therapy | Phase 4 | Recruiting | Instituto Mexicano del Seguro Social | 78 | 2025-07-10 | 2026-07-01 |
| Exploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a Diagnostic Tool for Partial and/or Total Non-compliance With Treatment Hair sampling and questionnaires answers for Patients with Lamivudine or Emtricitabine treatment - HIV (Human Immunodeficiency Virus) | Recruiting | University Hospital, Toulouse | 30 | 2025-07-03 | 2026-03-23 | |
| Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully Doravirine 100Mg Tab and Lamivudine 300 Mg Tab, Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab - HIV-1-infection | Phase 2 | Recruiting | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | 408 | 2025-04-30 | 2025-06-11 |
| STARLITE for Unresectable High-Grade Gliomas Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine - High Grade Glioma | Phase 1 | Recruiting | University of Miami | 24 | 2025-04-15 | 2026-06-25 |
| DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection Doravirine + tenofovir DF + lamivudine, Dolutegravir + tenofovir DF + lamivudine or emtricitabine - HIV-1-infection | Phase 3 | Recruiting | ANRS, Emerging Infectious Diseases | 610 | 2025-01-27 | 2026-07-27 |
| RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq) - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Macquarie University, Australia | 12 | 2024-11-15 | 2025-06-08 |
| A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI) Lamivudine 300 MG - Mild Cognitive Impairment | Phase 2 | Active not recruiting | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 23 | 2024-10-28 | 2025-12-04 |
| Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT) DOVATO - HIV-1-infection, Opioid Use Disorder | Phase 4 | Not yet recruiting | Saskatchewan Health Authority - Regina Area | 40 | 2024-09-30 | 2024-08-30 |
Showing 20 of 422. Sign in to see all of them.
HIV Infections (228) · Acquired Immunodeficiency Syndrome (72) · Hepatitis B, Chronic (42) · Hepatitis B (25) · Infections (13) · AIDS-Related Complex (12) · Tuberculosis (9) · Carcinoma, Hepatocellular (6) · Lipodystrophy (6) · HIV Seropositivity (5) · Pregnancy Complications, Infectious (5) · Breast Feeding (4) · Fibrosis (4) · Body Weight Changes (3) · Cardiovascular Diseases (3)
National Institute of Allergy and Infectious Diseases (NIAID) (68) · Glaxo Wellcome (20) · Bristol-Myers Squibb (17) · ViiV Healthcare (17) · Merck Sharp & Dohme LLC (15) · ANRS, Emerging Infectious Diseases (10) · Hoffmann-La Roche (8) · Kirby Institute (8) · Gilead Sciences (7) · GlaxoSmithKline (7) · French National Agency for Research on AIDS and Viral Hepatitis (6) · Fundación Huésped (5) · Abbott (4) · Alexion Pharmaceuticals, Inc. (4) · Boehringer Ingelheim (4)
United States (187) · Puerto Rico (48) · Spain (37) · China (34) · South Africa (32) · Canada (31) · France (29) · United Kingdom (26) · Italy (25) · Thailand (24) · Argentina (22) · Australia (22) · Brazil (19) · Germany (19) · South Korea (18)
Havlir D (3) · Jun Yong Park, M.D (3) · Kuritzkes D (3) · Richman D (3) · Sang Hoon Ahn, M.D.Ph.D (3) · Scott Hammer (3) · Andrew D Carr, MD (2) · Babafemi Taiwo, MBBS (2) · David A Cooper, MD (2)
PMID 24326304, PMID 33901188, PMID 15687448, PMID 16148846, PMID 18090046, PMID 20133267, PMID 24979445, PMID 32829410, PMID 34913844, PMID 38160309, PMID 40672760, PMID 41280318, PMID 10659875, PMID 10954886, PMID 11306155, PMID 11372025, PMID 11813503, PMID 11840078, PMID 11880966, PMID 11915000, PMID 11927734, PMID 11980557, PMID 12537512, PMID 14668455, PMID 14668456, PMID 14669723, PMID 15115831, PMID 15187476, PMID 15213559, PMID 15793367, PMID 15892437, PMID 15907596, PMID 16048984, PMID 16103764, PMID 16159645, PMID 16267764, PMID 16280696, PMID 16287792, PMID 16547789, PMID 16782488, PMID 16810109, PMID 16816555, PMID 16905783, PMID 17109339, PMID 17174704, PMID 17239478, PMID 17280617, PMID 17310819, PMID 17357053, PMID 17392561
2014 (6), 2017 (5), 2015 (4), U01AI068632 (4), 2008 (2), 2023 (2), U19AI053217 (2), 2004 (1), 2009 (1), 2016 (1), 2018 (1), 2019 (1), 2025 (1), 2UM1AI068636 (1), 5UM1AI068634 (1)